{"classes":[{"categories":[{"measurements":[{"comment":"No progressions","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"9.2"},{"comment":"No progressions","groupId":"OG002","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"}],"units":"Participants"}],"description":"The distribution of progression-free survival will be estimated by arm using the method of Kaplan-Meier.","groups":[{"description":"Patients receive bortezomib SC on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.","id":"OG000","title":"Arm A"},{"description":"Patients receive bortezomib SC as in Arm A, cyclophosphamide PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24, and dexamethasone PO on days 1 and 15 of courses 1-12 and day 1 of courses 13-24.","id":"OG001","title":"Arm B"},{"description":"Patients receive bortezomib SC as in Arm A and lenalidomide PO QD on days 1-28.","id":"OG002","title":"Arm C"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"From registration to the earliest date of documentation of disease progression or death due to any cause, assessed up to 3 years","title":"Progression-free Survival","type":"SECONDARY","unitOfMeasure":"Months to Progression"}